Physician profile
Derrick Cheung
NPI 1124274451
$1,995.98
in general payments reported to CMS, 2019-2025
22 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $88.73 · 2021: $382 · 2022: $614 · 2023: $434 · 2024: $236 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $970.50 | 2019-2025 | Durysta |
| Boston Scientific Corporation | $186.01 | 2019-2025 | Overstitch Endoscopic Suturing System, Exalt Model D |
| Janssen Biotech, INC. | $123.13 | 2022-2023 | Imbruvica |
| Gilead Sciences, INC. | $80.50 | 2021-2023 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.52 | 2020-2025 | Xifaxan |
| Braintree Laboratories, INC. | $59.57 | 2024 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $50.64 | 2024-2025 | Voquezna |
| W. L. Gore & Associates, INC. | $50.19 | 2021-2022 | |
| Cook Medical LLC | $48.45 | 2021 | |
| Nestle Healthcare Nutrition INC. | $47.34 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.19 | 2022-2025 | Gattex |
| Olympus America INC. | $34.57 | 2021 | |
| Daiichi Sankyo INC. | $29.94 | 2022 | |
| Apollo Endosurgery US INC | $26.61 | 2019 | |
| Erbe USA INC | $25.00 | 2023 | Erbe Vio3 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $24.89 | 2022 | |
| Eisai INC. | $24.86 | 2023 | |
| Covidien LP | $23.41 | 2019 | |
| Celgene Corporation | $21.26 | 2022 | |
| Capsovision, INC. | $20.50 | 2025 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $18.70 | 2021 | |
| Steris Corporation | $14.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.